Doravirine

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine
Clinical data
Trade namesPifeltro
Other namesMK-1439
AHFS/Drugs.comMonograph
MedlinePlusa618048
License data
Routes of
administration
By mouth[1][2]
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.234.454
Chemical and physical data
FormulaC17H11ClF3N5O3
Molar mass425.75 g·mol−1
3D model (JSmol)

Doravirine was approved for medical use in the United States in August 2018.[5]

References

  1. "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
  2. Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
  3. "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 1 October 2020.
  4. "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  5. "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
  • "Doravirine". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.